We developed a competition assay to compare, in a quantitative manner, the ability of human nucleotide excision repair (NER) to recognise structurally different forms of DNA damage. This assay uses a NER substrate consisting of M13 double-stranded DNA with a single and uniquely located acetylaminofluorene (AAF) adduct, and measures the efficiency by which multiply damaged plasmid DNA competes for excision repair of the site-directed modification. To validate this assay, we tested competitor DNA containing defined numbers of either AAF adducts or UV radiation products. In both cases, repair of the site-directed NER substrate was inhibited in a damage-specific and dose-dependent manner. We then exploited this competition assay to determine the susceptibility of bulky adozelesin-DNA adducts to human NER.
INTRODUCTION
Nucleotide excision repair (NER) is a multistep process that catalyses incision of damaged DNA strands on either side of the lesions and removes DNA damage as a component of oligonucleotide segments (1-4). The correct sequence is then reestablished by DNA repair synthesis, followed by ligation of the repair patches to the preexisting strands. In eukaryotes, NER incises DNA at the 3rd to 5th phosphodiester bond 3′ to the lesion, and at the 21st to 25th phosphodiester bond on the 5′ side, yielding damage-containing oligomers of 27-29 residues in length (2, 5) .
Most eukaryotic cells depend on NER to remove the principal forms of DNA damage induced by ultraviolet (UV) radiation (2, 3, 6) . However, NER-defective yeast or human (xeroderma pigmentosum) cells display hypersensitivity to killing by a very broad spectrum of genotoxic agents (7, 8) , indicating that this system is involved in the excision of virtually any kind of bulky DNA modification. In vitro studies with human cell extracts confirmed that NER is a versatile mechanism that processes a wide range of base adducts, such as, for example, those generated by the carcinogen N-acetoxy-2-acetylaminofluorene or the chemotherapeutic agents cis-diamminedichlorplatinum and psoralen (9) (10) (11) (12) . On the other hand, it was found that these adducts are recognised and removed by human NER with markedly different efficiencies (13) . A heterogeneous NER response is also indicated by the kinetics of photoproduct removal in UV-irradiated human cells. In fact, pyrimidine pyrimidone photoproducts are excised with a significantly shorter half-life than cyclobutane pyrimidine dimers (14, 15) . In the present study, we have set up a novel assay to analyse the substrate preferences of human NER in a quantitative manner. This assay is based on the ability of damaged plasmids to compete with a site-specific acetylaminofluorene (AAF) adduct. Using this competition assay, we observed that UV radiation products are recognised 30 times less effectively than the AAF modification, while bulky adducts produced by adozelesin, an antitumor antibiotic of the cyclopropylpyrroloindole type, are largely refractory to recognition by human NER in vitro.
MATERIALS AND METHODS

Enzymes
T4 polynucleotide kinase and T4 DNA ligase were purchased from Gibco-BRL. Restriction enzymes were purchased from New England Biolabs. Creatine phosphokinase and ribonuclease A were from Boehringer Mannheim.
Modified oligonucleotide
The 19 nucleotide (nt) oligomer 5′-ACCACCCTTCGAACCA-CAC-3′ was phosphorylated by incubation with ATP and T4 polynucleotide kinase, and reacted with N-acetoxy-2-acetylaminofluorene (NCI Chemical Carcinogen Reference Standard Repository) to form an AAF adduct at the single guanine residue (10) .
Construction of closed circular DNA containing a site-specific AAF adduct
The method used to produce site-specifically modified M13 DNA was adapted from Comess et al. (16) , and is based on the construction of a gapped intermediate consisting of a circular (+)strand and a linear (-)strand (17) . This gapped intermediate contains a single-stranded region of 19 nt that is complementary to the 19mer oligonucleotide described above. Briefly, the M13 derivative M13mp19G was obtained by ligating the synthetic duplex:
5′-GGTGTGGTTCGAAGGGTGGT-3′ 3′-ACGTCCACACCAAGCTTCCCACCAGATC-5′ * To whom correspondence should be addressed into the PstI-XbaI site of M13mp19 double-stranded DNA, followed by transfection of the ligation product into Escherichia coli strain DH5αF′. The resulting single-stranded DNA provides the (+)strand of the gapped intermediate. The complementary (-)strand was obtained by ligation of the duplex:
into the PstI-XbaI site of M13mp19 DNA, generating a second M13 derivative designated M13mp19Hb5. The insert in this DNA molecule contains the restriction sites for AatII (5′-GACGT′C) and ApaLI (5′-G′TGCAC). After amplification in strain DH5αF′, M13mp19Hb5 DNA was linearised by digestion with AatII and ApaLI, and the obtained large fragment was separated by gel filtration chromatography. M13mp19G single-stranded DNA (typically 1.2 mg) and the large fragment of M13mp19Hb5 (200 µg) were coincubated for 3 min at 95_C, followed by 15 min at 65_C and 2 h at room temperature in a volume of 0.6 ml containing 60 mM Tris-HCl, pH 8.0, 100 mM NaCl and 10 mM EDTA. The resulting gapped circular DNA was purified by benzoylated naphthoylated DEAE cellulose (Sigma) and ethanol precipitation as indicated (18) . Modified 19mer oligonucleotides were then ligated into this intermediate in 0.9 ml reactions containing 30 µg M13 gapped DNA, 0.5 µg phosphorylated oligonucleotides and 50 U T4 DNA ligase in 50 mM Tris-HCl, pH 7.6, 10 mM MgCl 2 , 1 mM ATP and 5% (w/v) polyethylene glycol 8′000. After incubations of 4 h at 16_C, covalently closed duplex DNA was purified by CsCl gradient centrifugation. Control M13 substrates were constructed by ligating unmodified 19mers into the gapped DNA.
Preparation of competitor DNA
Plasmid pUC19 was prepared by alkaline lysis from Escherichia coli strain DH5α grown without chloramphenicol amplification, and purified by CsCl followed by 5-20% sucrose gradient centrifugation (19) . To obtain AAF-DNA adducts, pUC19 (50 µg/ml) was reacted with 0.1 mM N-acetoxy-2-acetylaminofluorene in 2 mM sodium citrate, pH 7.0, at 25_C for 3 h. The unreacted carcinogen was then extracted five times with ether as described (20) , and DNA was precipitated with ethanol and repurified through a 5-20% sucrose gradient. Using radioactively labelled [ 3 H]N-acetoxy-2-acetylaminofluorene (NCI Chemical Carcinogen Reference Standard Repository), we determined that this modification protocol produced 10.2 ± 0.9 AAF adducts/ pUC19 molecule. For UV irradiation, aliquots of 20 µl containing pUC19 plasmids (100 µg/ml) in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA were placed on ice in an open Petri dish and irradiated at a dose rate of 2 J . m -2. s -1 using a germicidal lamp with peak output at 254 nm. The UV fluence was monitored with a Steritest dosimeter. Adozelesin-DNA adducts were prepared by incubating pUC19 (333 µg/ml) with 3.3 µM adozelesin in 1.5 mM sodium citrate, pH 7.0, and 15 mM NaCl for 120 min at 25_C, followed by ethanol precipitation and 5-20% sucrose gradient centrifugation. In aqueous solutions, the UV absorption spectrum of adozelesin is characterised by two peaks at 315 and 370 nm, with a molar extinction coefficient of 21 000 at 370 nm (data not shown). This latter value was used to estimate the frequency of adozelesin modification after UV spectrophotometry of the purified drug-plasmid DNA complexes (13.1 DNA adducts/pUC19). 
Repair competition assay
HeLa cell extracts were prepared by the method of Manley et al. (21) . Reactions (50 µl) were slightly modified from Hansson et al. (10) and contained HeLa cell extract (80 µg of proteins), 50 or 100 ng M13 DNA, various amounts of competitor pUC19 DNA, 45 mM HEPES, pH 7.8, 70 mM KCl, 7.4 mM MgCl 2 , 0.9 mM dithiothreitol, 0.4 mM EDTA, 3.4% glycerol, 2 mM ATP, 20 µM each of dATP, dGTP and dTTP, 8 µM dCTP, 2.0 µCi [α-32 P]dCTP (3000 Ci/mmol), 40 mM phosphocreatine, 2.5 µg creatine phosphokinase and 18 µg bovine serum albumin. After 3 h at 30_C, reactions were stopped by the addition of EDTA to 20 mM. The samples were incubated at 37_C with ribonuclease A (80 µg/ml) for 10 min, SDS to 0.5% and proteinase K to 190 µg/ml were then added, and the mixtures incubated for a further 45 min at 37_C. DNA was extracted, digested with AvaII, SmaI and PstI, and analysed by 20% polyacrylamide gel electrophoresis and autoradiography. This enzymatic restriction produces SmaI-PstI fragments of 37 base pairs (bp) containing the NER patches. Nucleotide incorporation within this 37mer fragment was quantified by scanning densitometry of the X-ray films on a Molecular Dynamics Computing Densitometer using ImageQuant software.
RESULTS
Basic design of the repair competition assay
As illustrated in Figure 1 , the repair competition assay is performed by coincubating in the same reaction a site-directed NER substrate and competitor DNA (plasmid pUC19) damaged with the lesion of interest. The assay measures the efficiency by which NER of the substrate is inhibited by the presence of DNA damage on the competitor. NER is the sole excision repair mechanism for bulky base adducts such as the AAF modification (2, 9, 11, 22) . Thus, competition for repair of a site-specific AAF adduct is expected if pUC19 contains lesions that are also recognised by the NER system.
Previous studies have demonstrated that incubation of AAFcontaining DNA in NER-proficient mammalian cell extracts results in the formation of repair patches of ∼30 residues in length (10) that extend over 3-5 nt 3′ and 21-25 nt 5′ to the site of modification (2, 5) . To measure these NER patches, we incubated M13 DNA containing the site-directed AAF adduct with HeLa cell extract in the presence of 32 P-labelled deoxynucleotides. After repair reactions of 3 h at 30_C, M13 DNA was recovered and cleaved with AvaII, SmaI and PstI, generating DNA fragments of 37, 330 and 6920 bp (Fig. 1) . In this experimental scheme, 30-nt long NER patches at the unique site of AAF modification are confined within the resulting SmaI-PstI fragments of 37 bp. To minimise the contribution of unspecific background incorporation, only these small SmaI-PstI fragments were considered for quantification of DNA repair synthesis.
Repair competition with AAF-damaged competitor
To validate the competition assay, we first tested the situation in which both substrate and competitor DNA contain the same lesion, i.e. AAF-DNA adducts. For that purpose we mixed singly modified M13 DNA substrate with pUC19 containing 10.2 ± 0.9 AAF adducts/molecule (see Materials and Methods for adduct quantification). This mixture of substrate (100 ng) and competitor DNA (50 ng) was incubated in HeLa cell extract in the presence of 32 P-labelled deoxynucleotides. Figure 2A shows reactions containing site-specifically modified M13 DNA (lanes 3 and 4, in duplicate), and control reactions containing unmodified substrate (lanes 1 and 2). Among the three fragments obtained by restriction digestion, only the 37mer SmaI-PstI fragment displayed ∼30-fold increased nucleotide incorporation in response to the site-directed AAF adduct, indicating NER of the bulky modification. This NER response was absent in reactions performed with extracts from XPA or XPC cells (data not shown). Nucleotide incorporation observed in the two long fragments of 330 and 6920 bp represents background DNA synthesis unrelated to NER, presumably initiated at nicks generated by unspecific nucleases (10, 22, 23) . Lanes 5 and 6 demonstrate that the specific NER response within the 37mer fragment was completely suppressed by the addition of 50 ng pUC19 competitor DNA containing an average of 10.2 AAF modifications. In contrast, the unspecific background synthesis into the long fragments of 330 and 6920 bp was not reduced by the presence of this competitor (lanes 5 and 6).
Dose dependence experiments demonstrated that inhibition of nucleotide incorporation into the SmaI-PstI fragment was already detectable in reactions containing 2.5 ng of multiply AAFdamaged pUC19. With increasing amounts of damaged competitor DNA, between 7.5 and 20 ng, DNA repair synthesis in the 37mer SmaI-PstI fragment was further reduced, and essentially abolished in the presence of 50 ng competitor DNA (Fig. 2B) . By interpolation of the data in Figure 2B , we calculated that 50% inhibition is expected in the presence of 3.4 ng competitor DNA, or at a M13 (100 ng) to pUC19 (3.4 ng) mass ratio of 29.4:1. Considering the different sizes of M13 double-stranded DNA (7287 bp) and plasmid pUC19 (2686 bp), these numbers translate to a molar ratio between the two DNA molecules of 10.8:1. Since M13 DNA contains only one AAF adduct/molecule whereas pUC19 contains an average of 10.2 AAF adducts/molecule, these calculations yield 50% inhibition of NER at a 1:1 stoichiometry of these lesions.
Repair competition with UV-irradiated competitor
UV radiation products are the most widely tested form of DNA damage. We therefore calibrated our system with competitor DNA 4) , but not into the corresponding fragment of unmodified control substrate (lanes 1 and 2). M13 DNA substrates (100 ng) were incubated with HeLa cell extract in the presence of radiolabelled deoxynucleotides. Among the three fractions obtained by restriction digestion of the reaction products, only the short SmaI-PstI 37mer displayed increased nucleotide incorporation resulting from NER of the site-directed adduct. This NER response was competitively inhibited by the addition of 50 ng multiply damaged AAF-damaged plasmids pUC19 (lanes 5 and 6). (B) Dose dependence experiment. M13 DNA substrate (100 ng) was incubated in HeLa extract with increasing amounts of multiply AAF-damaged pUC19, as indicated. Incorporation of radiolabelled deoxynucleotides into the 37mer SmaI-PstI fragment was quantified by scanning densitometry (mean values of two to three independent experiments). The inset shows a representative autoradiograph visualising the radiolabelled 37mer fragments.
exposed to different doses of UV radiation at 254 nm wavelength. M13 DNA substrate containing the site-directed AAF adduct (50 ng) was mixed with an identical amount of pUC19 competitor DNA that was either untreated or UV-irradiated. No inhibition of nucleotide incorporation into the 37mer fragment of M13 DNA was obtained in the presence of unmodified pUC19 (see Fig. 4 ), demonstrating that NER is not suppressed by undamaged competitor. However, nucleotide incorporation into the 37mer fragment was progressively reduced with increasing exposure of competitor DNA to UV light (Fig. 3) . Thus, UV radiation products effectively compete with the AAF substrate for NER. Half-maximal inhibition was found at doses ∼450 J . m -2 , while ∼20% of control activity was detected at 900 J . m -2 . This dose dependence yielded a nearly linear relationship between 200 and 1200 J . m -2 when the data was plotted on a logarithmic scale (Fig. 3) . In a previous report, UV treatment at 450 J . m -2 has been shown to induce a total of 15-16 UV radiation products on a plasmid of 3658 bp (24) . Irradiation of the smaller plasmid pUC19 with an identical dose is expected to induce 11-12 UV photoproducts/pUC19. Taken together, UV-irradiated competitor DNA containing 11-12 lesions/plasmid inhibited repair of the AAF substrate to ∼50% at a M13 substrate to pUC19 competitor mass ratio of 1:1, corresponding to a molar ratio between the two DNA molecules of 1:2.7.
Repair competition with adozelesin-modified DNA
Adozelesin is the lead compound for a series of synthetic DNA-reactive agents that have entered clinical trials for potential use as antitumor drugs (25, 26) . These agents alkylate DNA at N3 of adenine with high selectivity and considerable sequence specificity, and generate bulky adducts that are mainly confined within the minor groove (27, 28) .
Plasmid pUC19 was reacted with adozelesin to obtain an average of 13.1 adducts/plasmid molecule, as estimated from the spectrophotometric analysis of purified drug-DNA complexes (see Materials and Methods). When tested in the competition assay, adozelesin-modified DNA was unable to compete with the repair of AAF adducts on the substrate, even when added in large excess (Fig. 4) . Specifically, adozelesin-modified pUC19 was tested at substrate to competitor mass ratios of 1:1 and 1:3, corresponding to molar ratios of 1:2.7 and 1:8.1, but no competitive inhibition was observed. The small inhibition found at the 1:8.1 molar ratio was not significantly different from that observed with identical amounts of undamaged pUC19. In parallel control reactions, AAF-or UV-damaged (500 J . m -2 ) pUC19 were effective competitors (Fig. 4) . 
DISCUSSION
The repair competition assay requires a site-directed NER substrate (M13 double-stranded DNA with a single AAF adduct in a unique sequence), competitor DNA (multiply damaged plasmid pUC19), and a NER-proficient extract prepared from HeLa cells. Although the assay was developed with human cell extracts, it should be applicable to rodent, Xenopus egg, or yeast extracts. The assay determines the capacity of a particular DNA lesion located on plasmid pUC19 to inhibit repair of the site-specific AAF adduct by competing for repair factors. As its main advantage, this novel method provides a biochemical assay for quantitative comparisons between structurally distinct DNA lesions.
Among the ∼30 polypeptides required for NER, those involved in early stages of the reaction have been shown to be present in limiting amounts. For example, addition of purified bacterial UvrABC nuclease to the human cell-free extract resulted in 5-fold enhancement of DNA repair synthesis at sites of AAF modification (10), indicating that damage recognition/DNA incision constitutes the rate limiting step in the human pathway. Thus, competition for these rate limiting factors allows to assess recognition by human NER in a highly quantitative manner. A strong inhibition indicates effective recognition of the lesions located on the competitor, while low or complete lack of inhibition indicates poor recognition. The AAF modification was chosen as the model substrate for these competition assays because its repair is strictly dependent on the NER pathway.
Another essential prerequisite for the repair competition assay is the absence of significant inhibition in the presence of undamaged plasmid pUC19. In fact, undamaged pUC19 was essentially unable to inhibit NER when added to the reaction mixture at a substrate to competitor molar ratio of 1:2.7, and produced only marginal inhibition at a molar ratio of 1:8.1. This limited effect in the presence of undamaged competitor is achieved by extensive purification of the circular covalently closed form of plasmid pUC19 using CsCl and sucrose gradient centrifugation, to eliminate contaminating material that may suppress NER unspecifically (19) . Additionally, to avoid inhibition by chemical residues after treatment with N-acetoxy-2-acetylaminofluorene or adozelesin, damaged plasmids were subjected to repeated purification steps including sucrose gradients.
In contrast with undamaged pUC19, both AAF-damaged and UV-irradiated pUC19 effectively inhibited NER of the site-specific adduct on the substrate. At a level of 10-12 lesions/plasmid, 50% inhibition was found at a molar ratio of substrate to competitor of 10.8:1 with AAF-damaged competitor, corresponding to a 1:1 stoichiometry of AAF adducts, but at a molar ratio between the two DNA molecules of 1:2.7 when UV-irradiated competitor was tested. Thus, AAF adducts are nearly 30 times more effective competitors than UV radiation products, indicating that human NER possesses a markedly higher affinity for the former type of lesion. This finding is consistent with previous reports demonstrating that the quantitatively more abundant UV photoproduct, the cyclobutane pyrimidine dimer, is processed in vitro (23, 24) and in vivo (14, 15) with only moderate efficiency. In summary, these experiments performed with well-studied lesions targeted by NER show that the competition assay provides a valuable and useful method to assess DNA damage recognition by NER in a quantitative manner.
In this report, we have exploited this competition assay to test the efficiency by which bulky adozelesin-DNA adducts are recognised by human NER. The susceptibility of these bulky adducts to NER has not been tested before. We found that pUC19 DNA containing an average of 13.1 adozelesin adducts/plasmid was unable to compete with the substrate even when added in large excess. In the comparison between different lesions, our results indicate that DNA adducts induced by this experimental chemotherapeutic agent are recognised by human NER at least 100-fold less efficiently than AAF adducts. This low recognition capacity may be associated with the unique structural properties of DNA adducts formed by adozelesin and related compounds (27, 28) . We are currently extending the repair competition assay to a broad spectrum of different bulky modifications to identify possible molecular determinants for recognition by the human NER system.
